Scarfo, LydiaChatzikonstantinou, ThomasRigolin, Gian MatteoQuaresmini, GiuliaMotta, MarinaVitale, CandidaGarcia-Marco, Jose AntonioHernandez-Rivas, Jose AngelMiras, FatimaBaile, MonicaMarquet, JuanNiemann, Carsten UReda, GianluigiMunir, TalhaGimeno, EvaMarchetti, MoniaQuaglia, Francesca MariaVarettoni, MarziaDelgado, JulioIyengar, SunilJanssens, AnnMarasca, RobertoFerrari, AngelaCuellar-Garcia, CarolinaItchaki, GiladŠpaček, MartinDe Paoli, LorenzoLaurenti, LucaLevin, Mark-DavidLista, EnricoMauro, Francesca RŠimkovič, MartinVan Der Spek, EllenVandenberghe, ElisabethTrentin, LivioWasik-Szczepanek, EwaRuchlemer, RosaBron, DominiqueDe Paolis, Maria RosariaDel Poeta, GiovanniFarina, LuciaFoglietta, MyriamGentile, MassimoHerishanu, YairHerold, TobiasJaksic, OzrenKater, Arnon PKersting, SabinaMalerba, LaraOrsucci, LorellaPopov, Viola MariaSportoletti, PaoloYassin, MohamedPocali, BarbaraBarna, GaborChiarenza, AnnalisaDos-Santos, GimenaNikitin, EugeneAndres, MartinDimou, MariaDoubek, MichaelEnrico, AliciaHakobyan, YervandKalashnikova, OlgaOrtiz-Pareja, MacarenaPapaioannou, MariaRossi, DavideShah, NimishShrestha, AmitStanca, OanaStavroyianni, NikiStrugov, VladimirTam, ConstantineZdrenghea, MihneaCoscia, MartaStamatopoulos, KostasRossi, GiuseppeRambaldi, AlessandroMontserrat, EmiliFoa, RobinCuneo, AntonioGhia, Paolo2023-02-092023-02-092020-07-09Scarfò, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 34(9), 2354-2363. https://doi.org/10.1038/s41375-020-0959-xhttp://hdl.handle.net/10668/15913Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.enPyrimidinesRetrospective StudiesSARS-CoV-2Severity of Illness IndexSurveys and QuestionnairesAdenineAge FactorsAgedAged, 80 and overAntineoplastic AgentsBetacoronavirusCOVID-19ComorbidityCoronavirus InfectionsFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPandemicsPiperidinesPneumonia, ViralPrognosisProtein Kinase InhibitorsPyrazolesresearch article32647324Restricted AccessMortalidadAncianoOportunidad relativaOxígenoLeucemia linfocítica crónica de células B10.1038/s41375-020-0959-x1476-5551PMC7347048https://www.nature.com/articles/s41375-020-0959-x.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347048/pdf